Text/Yangcheng Evening News All Media Reporter Zhang Hua
Photo/Visual China
Recently, the results of the sixth batch of nationally organized centralized drug procurement (insulin special) were announced, with an average of 48% The decline is undoubtedly good news for the more than 10 million patients who use insulin. Endocrinologists said that after the price reduction of insulin, drugs that are more convenient to use, less risk of hypoglycemia, and fewer side effects have emerged, which will not only reduce the burden of medication for patients, but also improve compliance, which will also help They receive clinical treatment more regularly.
A more convenient treatment plan is needed to control blood sugar
According to the reporter’s understanding, many patients do not pay attention to active treatment when they are first diagnosed with diabetes. Treatment, blood sugar control is not ideal, and finally led to complications. Liu Ping (pseudonym), a patient with diabetes for many years, is one of the “disobedient” members. It is reported that he was diagnosed with type 2 diabetes in 2005. Due to the complications of fundus disease at the time of diagnosis, the doctor formulated an insulin treatment plan for him.
After a period of treatment, Liu Ping’s blood sugar has indeed been controlled relatively stably. But after the stabilization, his mentality changed, and he relaxed blood sugar control from time to time. For example, the human insulin he used needed to be injected exactly 30 minutes before meals. But he kept forgetting, and was hospitalized for hypoglycemia several times because he missed the injection time.
How to better control blood sugar? According to Liu Ping’s personal situation, the doctor advised him to change the human insulin to insulin analogs. “Clinical studies have shown that third-generation insulin is more effective in terms of efficacy, and more importantly, it is more convenient to use, has less risk of hypoglycemia, and has fewer side effects. Therefore, for patients without allergic reactions and other adverse reactions, it is effective and safe. The hidden dangers of sex are very low.” Professor Yoshiaki Mu of the Endocrinology Department of the Chinese People’s Liberation Army General Hospital said in an interview with the media.
“Insulin analogues are more convenient to use. But I can’t afford the drug cost.” Liu Ping said, “My retirement salary is not high, and I don’t want to put too much burden on my son.” The doctor agreed that Liu Ping quietly switched to oral hypoglycemic drugs, but as a result, the blood sugar control was not up to standard, and complications followed again, and he had to be admitted to the hospital for treatment.
The policy of benefiting the people has played a major role in promoting diabetes treatment
Recently, the sixth batch of nationally organized centralized procurement of drugs (insulin Special) results are announced, this centralized procurement includes prandial human insulin, basal human insulin, premixed human insulin, prandial insulin analogs, basal insulin analogs, and premixed insulin analogs, a total of 6 procurement groups, the procurement cycle for two years. Among them, the largest decrease was the protamine zinc recombinant insulin lispro mixed injection 25 and 50 in the premixed insulin analog group, with a single minimum price of only 18.89 yuan, a decrease of 73%.
“It’s good, it’s cheap and affordable. I’m so grateful for the country’s good policy.” Liu Ping said.
In this regard, doctors from all over the country have also expressed that after the insulin price reduction, patients’ medication burden will be reduced, patients’ compliance will be better, and it will also help them receive clinical treatment more regularly. Statistics show that more than 10 million patients use insulin nationwide. In recent years, the growth rate of China’s insulin market has also exceeded the global average growth rate.
“For our Chinese diabetic patients, if they used second-generation insulin (human insulin) in the past, the actual annual expenditure was about 1,500 yuan. If they used third-generation insulin (insulin analogs) ), the annual expenditure is 2000-3000 yuan. If the overall can be reduced by more than 48%, the annual expenditure will be reduced by about half, and the reimbursement of medical insurance will greatly reduce the cost of patients and the burden of medical care.” Shanghai Jiaotong University Professor Peng Yongde, director of the Department of Secretion and Metabolism of the First Affiliated People’s Hospital, pointed out in an interview with the media: “This centralized procurement is actually more of a policy of benefiting the people, which can play a significant role in promoting and helping the treatment of diabetic patients in my country. “
According to the reporter’s understanding, according to the previous work arrangement of the National Drug Joint Purchasing Office, from May 2022, the results of the sixth batch of national drug centralized procurement will be officially implemented, and the specific implementation date will be announced by local governments. prevail. Recently, all provinces are actively preparing for the landing. As of now, Fujian, Guangdong, Shanghai, Gansu, Heilongjiang, Yunnan, Liaoning and other places have issued notification notices. According to the rules of centralized procurement, after completing the preparatory work such as hanging the network, the winning result will be officially implemented soon. On the official landing date, the selected products will generally enter the purchasable state directly from 0:00 on that day. (For more news, please pay attention to Yangcheng Pie pai.ycwb.com)